Sio Gene Therapies (NASDAQ:SIOX) announced its quarterly earnings data on Wednesday. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.17, MarketWatch Earnings reports.
Shares of NASDAQ:SIOX opened at $2.41 on Thursday. The business has a 50 day simple moving average of $2.43. Sio Gene Therapies has a twelve month low of $1.86 and a twelve month high of $5.74. The company has a market cap of $113.87 million and a PE ratio of -0.82.
SIOX has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Sio Gene Therapies in a research report on Wednesday, May 5th. Zacks Investment Research downgraded shares of Sio Gene Therapies from a “buy” rating to a “hold” rating in a report on Saturday, April 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Sio Gene Therapies in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $10.92.
About Sio Gene Therapies
Sio Gene Therapies, Inc, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis.
See Also: Why are trading ranges significant?
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.